BiotechTube

Selinexor + Ixazomib

Phase 1Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma

Trial Timeline

Nov 1, 2020 → Nov 24, 2020

NCT ID
NCT03880123

About Selinexor + Ixazomib

Selinexor + Ixazomib is a phase 1 stage product being developed by Karyopharm Therapeutics for Liposarcoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03880123. Target conditions include Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03880123Phase 1Withdrawn

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
efatutazoneDaiichi SankyoPhase 2
35
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
35
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
PF-07220060 + MidazolamPfizerPhase 2
39
Sunitinib Malate (SU011248)PfizerPhase 2
35
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28